Dr. John Cush RheumNow
3 years 5 months ago
Bone marrow edema was found in healthy individuals, Denis Poddubnyy #RNL2023 @RheumNow https://t.co/1n6E2QuGut https://t.co/y9Zzw6rdqN
Dr. John Cush RheumNow
3 years 5 months ago
What to look for( MRI ), Denis Poddubnyy #RNL2023 @RheumNow
STIR: inflammation
T1 erosion, fatty changes
VIBE: erosion https://t.co/enHned1acr
Dr. John Cush RheumNow
3 years 5 months ago
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
https://t.co/oNTKZXSrzn https://t.co/OlbCuSuLlo
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA). This has implications on diagnosis and population care. A recent analysis of Norway registry data answers this question.
Dr. John Cush RheumNow
3 years 5 months ago
In the UK, MHRA has somewhat softened its warnings on Febuxostat use in gout - stating use caution if considering Febuxostat in patients with a prior history of major cardiovascular disease; esp w/ high urate and tophi burden or starting ULT https://t.co/y0KhXtgzzG https://t.co/5ZlE0XK8qx
Dr. John Cush RheumNow
3 years 5 months ago
The Burden of Chronic Pain in US Adults (2019-2020)
Analysis of National Health Interview Survey data shows that the incidence of chronic pain in the USA is high compared with other chronic diseases.
https://t.co/mH6Zb3i3Vw https://t.co/PWI8R6mKJR
Dr. John Cush RheumNow
3 years 5 months ago
J&J lawsuit against Amgen (Nov 2022) over Amgens biosimilar of Stelara has been settled (terms undisclosed) such that the Amgen biosimilar cannot be US marketed until 1/1/2025. Stelaras 2022 revenue was $9.7 billion https://t.co/NVgBsBNxk1 https://t.co/Fj8rn05RW0
Dr. John Cush RheumNow
3 years 5 months ago
Women’s health research lacks funding – these charts show how -- Nature has published a very slick/graphical representation of the deficient research funding (US NIH & UK UK Medical Research Council) of diseases affecting women. https://t.co/hJ8DzKxHeW https://t.co/aHoQTKOlRF
The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.
Dr. John Cush RheumNow
3 years 5 months ago
With all the new adalimumab biosimilars happening in 2023, where's the pen? Now the FDA has approved an ADA biosimilar, Cyltezo, Autoinjector Pen! https://t.co/yyyPa9d2Ye https://t.co/MuAnfJ0DsB
Dr. John Cush RheumNow
3 years 5 months ago
A call for the NIH to address disparities in women’s health research funding. In 1993 Congress mandated NIH include women/minorities in clinical trials. But 30 yrs later, only 11% of NIH budget went to womens diseases https://t.co/8yzUTD1Ufq https://t.co/27W6MnRCFx
Dr. John Cush RheumNow
3 years 5 months ago
Retrospective cross-sectional EMR study from Israel compared GI Dz in 18,598 FM pts vs 36,985 controls. FM significantly assoc w/ IBS (OR 4.61), GERD (OR 2.62), PUD (OR 2.13), celiac Dz(OR 2.08), IBD ; But not w/ GI malignancies https://t.co/mpLb3rE0CB https://t.co/mySSXC5sjA
